CareLit · DOI-Nachweis · Pneumologie
A randomized phase 2 study of pemetrexed vs. pemetrexed+erlotinib in second-line treatment for locally advanced or metastatic, non-squamous NSCLC
DOI 10.1055/s-0032-1302878
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ von Pawel, Z Papai-Szekely, N Vinolas, C Sederholm, M Klima, D Desaiah, M Leschinger, C Dittrich
ZeitschriftPneumologie
Ausgabe02/2012
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: PEM and ERL have been approved as second-line monotherapy for locally advanced or metastatic NSCLC. The combination of PEM + ERL showed synergistic activity in preclinical studies. This multicenter, randomized, open-label study assessed the efficacy and safety of PEM + ERL vs. PEM. Methods: Patients (pts) with NSQ NSCLC who have failed one prior platinum-based chemotherapy regimen for advanced or metasta…
Zitieren
Zitierempfehlung
J von Pawel, Z Papai-Szekely, N Vinolas, C Sederholm, M Klima, D Desaiah, M Leschinger, C Dittrich (2012) A randomized phase 2 study of pemetrexed vs. pemetrexed+erlotinib in second-line treatment for locally advanced or metastatic, non-squamous NSCLC. Pneumologie (02). https://doi.org/10.1055/s-0032-1302878
Mit CareLit weiterarbeiten